Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||CGM097 + Dabrafenib + Navitoclax + PF-04217903|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|CGM097||NVP-CGM097||MDM2 Inhibitor 19||CGM097 binds to the p53 binding region of MDM2 and prevents MDM2-p53 interaction, resulting in activation of p53 signaling and decreased tumor growth (Cancer Res October 1, 2014 74:4638, PMID: 32651541).|
|Dabrafenib||Tafinlar||GSK2118436||BRAF Inhibitor 20||Tafinlar (dabrafenib) inhibits the activity of BRAF, including V600E, which results in inhibition of tumor cell proliferation (PMID: 22735384). Tafinlar (dabrafenib) is FDA approved for BRAF V600E positive unresectable or metastatic melanoma, and in combination with Mekinist (trametinib) for BRAF V600E/K-mutant melanoma, BRAF V600E-mutant non-small cell lung cancer, and BRAF V600E-mutant anaplastic thyroid cancer (FDA.gov).|
|Navitoclax||ABT-263||BCL-XL inhibitor 11 BCL2 inhibitor 18||Navitoclax (ABT-263) is a BCL2, BCL-XL, and BCL-W inhibitor, which may enhance the efficacy of chemotherapeutics (PMID: 25787766, PMID: 32513939).|
|PF-04217903||PF04217903||MET Inhibitor 51||PF-04217903 binds to MET and inhibits its activation, resulting in decreased activation of downstream signaling, and potentially resulting in decreased tumor cell growth and migration and increased tumor cell death (PMID: 28599617).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|